Next Article in Journal / Special Issue
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
Previous Article in Journal / Special Issue
Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence
 
 
Review

Article Versions Notes

Cancers 2018, 10(6), 173; https://doi.org/10.3390/cancers10060173
Action Date Notes Link
article xml file uploaded 31 May 2018 15:55 CEST Original file -
article xml uploaded. 31 May 2018 15:55 CEST Update https://www.mdpi.com/2072-6694/10/6/173/xml
article pdf uploaded. 31 May 2018 15:55 CEST Version of Record https://www.mdpi.com/2072-6694/10/6/173/pdf
article html file updated 31 May 2018 15:56 CEST Original file -
article html file updated 25 June 2018 11:53 CEST Update -
article html file updated 30 March 2019 06:20 CET Update -
article html file updated 16 April 2019 15:34 CEST Update -
article html file updated 30 April 2019 15:00 CEST Update -
article html file updated 9 February 2020 19:45 CET Update https://www.mdpi.com/2072-6694/10/6/173/html
Back to TopTop